At a glance
ClinicalIndex Comparison RecordN/AActive· 3,656 enrolled
Drug / intervention
1mg Dexamethasone testother
Likely dose
1mg Dexamethasone testfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas - Substudy of the ENSAT (European Network for the Study of Adrenal Tumor) Registry
In Brief
An observational study evaluating 1mg Dexamethasone test for Adrenal Incidentaloma. Active but no longer recruiting, targeting 3,656 participants across 2 sites in 2 countries.
Detailed Summary
The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdrenal Incidentaloma
CountriesGermany, Italy
CollaboratorsEuropean Network for the Study of Adrenal Tumors
Timeline
N/AActiveOverdue
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
Primary CompletionAug 2019
First PostedJun 2021
Study CompletionDec 2025
TodayJul 2026
First PostedJun 8, 2021
Enrollment StartJan 1, 2015
Primary CompletionAug 31, 2019
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 5.1 years ago
Interventions
1mg Dexamethasone testother
For each patient a 1mg dexamethasone test has been performed.